Boehringer Ingelheim Corporation

Type: Company
Name: Boehringer Ingelheim Corporation
First reported Jul 10 2014 - Updated Jul 10 2014 - 1 reports

U.S. FDA Accepts NDA Filing for Boehringer Ingelheim’s Nintedanib for Idiopathic Pulmonary Fibrosis

nintedanibTreatment for Idiopathic Pulmonary Fibrosis Ridgefield, Conn., July 2, 2014 – Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the New Drug Application (NDA) for its investigational compound nintedanib has been accepted for filing ... [Published Drugs.com - Jul 10 2014]
First reported Jul 08 2014 - Updated Jul 09 2014 - 1 reports

Sanofi sues Eli Lilly over insulin rival to Lantus

Through its complaint made public on Tuesday in the U.S. District Court in Wilmington, Delaware, Sanofi is seeking to halt Lilly's proposed commercial marketing in the United States of a rival treatment, known as Abasria, saying the sale would violate ... [Published NewsRT.co.uk - Jul 08 2014]
First reported Jul 02 2014 - Updated Jul 02 2014 - 1 reports

Boehringer Ingelheim Corporation Submits Applications In Europe For Tiotropium + Olodaterol Respimat® Fixed-Dose Combination In COPD

7/2/2014 10:54:41 AMINGELHEIM, Germany--(BUSINESS WIRE) For media outside the US, the UK and Canada.Boehringer Ingelheim today announced submission of Marketing Authorisation Applications in 31 European countries for the once-daily fixed-dose combination ... [Published BioSpace - Jul 02 2014]
First reported Jun 30 2014 - Updated Jun 30 2014 - 1 reports

CHMP recommends Lilly/Boehringer's new insulin glargine product for approval in EU to treat type 1 and type 2 diabete

The Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval for the investigational compound LY2963016, a new insulin glargine product, for the treatment of type 1 and type 2 diabetes. The new insulin glargine ... [Published PharmaBiz - Jun 30 2014]
First reported Jun 27 2014 - Updated Jun 27 2014 - 1 reports

Boehringer Ingelheim Discontinues Faldaprevir, Halts HCV Drug Development

Details Category: Experimental HCV Drugs Published on Friday, 27 June 2014 00:00 Written by Boehringer IngelheimBoehringer Ingelheim has announced that it will discontinue development of its investigational hepatitis C virus (HCV) protease inhibitor faldaprevir, ... [Published HIV and Hepatitis.com - Jun 27 2014]
First reported Jun 26 2014 - Updated Jun 27 2014 - 1 reports

Boehringer Ingelheim's Investigational Antidote for Pradaxa® (dabigatran etexilate mesylate) Receives FDA Breakthrough Therapy Designation

/PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to idarucizumab*, an investigational fully humanized antibody fragment, or Fab, being ... [Published BusinessWeek - Jun 26 2014]
First reported Jun 20 2014 - Updated Jun 20 2014 - 1 reports

Boehringer Ingelheim Corporation Release: New Pradaxa® Clinical Study To Explore Practical Management Of Patients With Atrial Fibrillation Undergoing Ablation

6/20/2014 10:37:12 AMINGELHEIM, Germany--(BUSINESS WIRE)--For media outside of the U.S., the UK & Canada only.Boehringer Ingelheim today announces a new study of Pradaxa® (dabigatran etexilate) in patients with atrial fibrillation (AF). The RE-CIRCUIT™ ... [Published BioSpace - Jun 20 2014]
First reported Jun 19 2014 - Updated Jun 19 2014 - 1 reports

Boehringer Ingelheim, Lilly resubmit SGLT2 inhibitor empagliflozin NDA to US FDA

Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company  announced the resubmission of a New Drug Application (NDA) for the investigational sodium glucose co-transporter-2 (SGLT2) inhibitor empagliflozin for the treatment of adults ... [Published PharmaBiz - Jun 19 2014]
First reported Jun 17 2014 - Updated Jun 17 2014 - 1 reports

Two phase III trials of empagliflozin/linagliptin combo tablet showed reduction in blood glucose levels in adults withT2D

Two phase III clinical trials found the investigational combination tablet of empagliflozin and linagliptin reduced blood glucose levels in adults with type 2 diabetes (T2D), Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company ... [Published PharmaBiz - Jun 17 2014]
First reported Jun 14 2014 - Updated Jun 14 2014 - 1 reports

Studies Show Investigational New Insulin Glargine -2-

Approximately 24.4 million Americans and an estimated 382 million people worldwide have type 1 or type 2 diabetes. Type 2 diabetes is the most common type, accounting for an estimated 85 to 95 percent of all diabetes cases. Diabetes is a chronic condition ... [Published Scottrade - Jun 14 2014]
First reported May 24 2014 - Updated May 24 2014 - 1 reports

EU grants marketing approval for Jardiance tabs to treat type 2 diabetes mellitus to improve glycemic control in adults

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company announced that the European Commission granted marketing authorization for Jardiance (empagliflozin) tablets, a sodium glucose co-transporter 2 (SGLT2) inhibitor, for the treatment of ... [Published PharmaBiz - May 24 2014]
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

US FDA accepts NDA filing of empagliflozin and linagliptin combo drug to treat adults with type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company announced that the US Food and Drug Administration (FDA) accepted the filing of the New Drug Application (NDA) for the investigational combination tablet of empagliflozin and linagliptin ... [Published PharmaBiz - Apr 16 2014]

Quotes

Lilly spokeswoman Tammy Hull said the Indianapolis-based company is reviewing Sanofi's latest lawsuit, and "does not believe the application infringes any of the asserted patents." Sanofi is based in Paris
...for the millions of patients in the EU who need basal insulin to help manage their diabetes," said Enrique Conterno, president, Lilly Diabetes. "This first-ever biosimilar insulin to receive a positive CHMP recommendation underscores Lilly and Boehringer Ingelheim's commitment to providing physicians and patients high-quality diabetes medicines, along with expertise and support tools they need to help manage the disease."
...expedite its development," said Sabine Luik, M D , senior vice president, Medicine & Regulatory Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "We are committed to innovative research and to advancing care in patients taking PRADAXA. We continue to investigate the potential of idarucizumab as a therapeutic option should a patient experience uncontrolled bleeding or need to undergo emergency surgery or another invasive procedure."
...and Professor of Cardiology and Director of the Electrophysiology Laboratory and Arrhythmia Service, Johns Hopkins Hospital, Baltimore Maryland . "This study will provide valuable insights regarding the practical management of NVAF patients requiring anticoagulation during these procedures."

More Content

All (17) | News (17) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
U.S. FDA Accepts NDA Filing for Boehringer Inge... [Published Drugs.com - Jul 10 2014]
Sanofi sues Eli Lilly over insulin rival to Lantus [Published NewsRT.co.uk - Jul 08 2014]
Sanofi sues Eli Lilly over insulin rival to Lantus [Published Reuters - Jul 08 2014]
Boehringer Ingelheim Corporation Submits Applic... [Published BioSpace - Jul 02 2014]
CHMP recommends Lilly/Boehringer's new insulin ... [Published PharmaBiz - Jun 30 2014]
Boehringer Ingelheim Discontinues Faldaprevir, ... [Published HIV and Hepatitis.com - Jun 27 2014]
Boehringer Ingelheim's Investigational Antidote... [Published BusinessWeek - Jun 26 2014]
Boehringer Ingelheim Corporation Release: New P... [Published BioSpace - Jun 20 2014]
Boehringer Ingelheim Initiates RE-CIRCUIT™ Tria... [Published Michigan Live - Jun 20 2014]
Boehringer Ingelheim, Lilly resubmit SGLT2 inhi... [Published PharmaBiz - Jun 19 2014]
Two phase III trials of empagliflozin/linaglipt... [Published PharmaBiz - Jun 17 2014]
Studies Show Investigational New Insulin Glargi... [Published Scottrade - Jun 14 2014]
EU grants marketing approval for Jardiance tabs... [Published PharmaBiz - May 24 2014]
US FDA accepts NDA filing of empagliflozin and ... [Published PharmaBiz - Apr 16 2014]
EU recommends approval of empagliflozin to redu... [Published PharmaBiz - Mar 24 2014]
CEO Cancer Gold Standard accreditation awarded ... [Published BioPortfolio - Dec 13 2013]
Visible Health Collaborating with Boehringer In... [Published PRWeb - Oct 02 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.